Avenzo Therapeutics closes $215M oversubscribed private placement to advance oncology pipeline
What's the deal? Avenzo Therapeutics, a clinical-stage biotech focused on next-generation cancer treatments, has closed a $215 million oversubscribed private placement. OrbiMed and SR OneDealroom has a profile for this one. Try Dealroom → led the round, with the Longwood FundDealroom has a profile for this one. Try Dealroom → joining as a new investor alongside all existing backers, including Foresite Capital.
The raise brings Avenzo's total funding to $446 million since the company's founding in 2022. It follows a $150 million Series A-1 in March 2024 and a $60 million Series B in September 2025.
Why now? Avenzo has expanded its clinical-stage pipeline from one to four assets since inception, including small molecule inhibitors and antibody-drug conjugates (ADCs) targeting advanced solid tumours and metastatic breast cancer. Its lead candidate, AVZO-021, is a selective CDK2 inhibitor currently in Phase 1 trials.
The fresh capital will fund the advancement of these programmes as the company pushes deeper into the clinic.
What could go wrong? Oncology drug development remains notoriously risky — most candidates fail in clinical trials. Avenzo's pipeline is still early-stage, and the leap from Phase 1 to regulatory approval is long and expensive. A competitive CDK inhibitor landscape also means the company will need strong differentiation to win market share, even if its drugs prove effective.
The signal: OrbiMed, one of the world's largest healthcare-dedicated investment funds, co-leading this round alongside SR One underscores the calibre of capital flowing into clinical-stage oncology. Avenzo's classification as a late-growth-stage company on Dealroom — despite being founded only in 2022 — suggests investors see a compressed timeline to value inflection, likely driven by the breadth of a four-asset pipeline in a sector where ADCs and selective inhibitors are commanding premium deal terms.
Read more: ainvest.com
